The USPTO recently published a final rule announcing that it would encourage the transition to filing in DOCX format by imposing new fees on certain documents submitted in a non-DOCX format. The new rule takes effect on April 3, 2023.*
The Mayo/Myriad standard arguably introduced a great deal of uncertainty into the feasibility of obtaining patent protection for life sciences innovations and has been accused of curtailing the competitiveness of U.S.-based life sciences companies in the global marketplace.
In 2016, the USPTO launched the Patents 4 Patients program to support the $1 billion National Cancer Moonshot initiative. In September of this year, the USPTO announced that the pilot program would be extended through January 31, 2023.
The United States Patent and Trademark Office (USPTO) and the World Intellectual Property Association (WIPO) have announced a partnership to facilitate the resolution of disputes related to standard essential patents (SEPs).
We are nearing the halfway point of 2022, with a new director at the USPTO, another opportunity to clarify the §101 patent eligibility framework, and a pair of bills poised to innovate the semiconductor industry. Here’s what you need to know about the year in patents so far.
The USPTO’s Patent Pro Bono Program, established in 2011 as a component of the Leahy-Smith America Invents Act, connects small business owners and inventors with pro bono representation to ease the burden of expensive and time-consuming patent prosecution.